HTG Molecular Diagnostics Announces Immuno-Oncology Research Collaboration Agreement with Bristol-Myers Squibb

HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced a research collaboration agreement with Bristol-Myers Squibb (NYSE:BMY) to evaluate the potential for immuno-oncology molecular profiling in multiple tumor types.

HTG Logo Spot-sized copy

The collaboration between HTG and Bristol-Myers Squibb will utilize the next generation sequencing (NGS)-based HTG EdgeSeq system as a tool for use in support of Bristol-Myers Squibb’s translational research activities.

“We believe this collaboration will provide many benefits to Bristol-Myers Squibb’s immuno-oncology development programs and further add to HTG’s industry leadership in the development of NGS-based molecular diagnostic assays toward the goal of precision medicine. This collaboration is the result of a long-standing Bristol-Myers Squibb/HTG relationship and we are excited to continue as a partner with Bristol-Myers Squibb’s translational research team,” said John Lubniewski, HTG’s Chief Business Officer.

Under the terms of the agreement, HTG will provide Bristol-Myers Squibb access to its NGS-based HTG EdgeSeq system and the companies will collaborate to develop tools for use for molecular profiling research for immuno-oncology.

“Immuno-oncology is a very important business segment for us and this agreement and the expansion of our relationship with BMS is a validation of our HTG EdgeSeq technology and value proposition,” stated TJ Johnson, President and CEO of HTG Molecular Diagnostics. “We firmly believe in the potential of immuno therapies in treating cancer patients and we are honored to be chosen as a profiling partner for Bristol-Myers Squibb, a recognized leader in this space.”

About HTG:

Headquartered in Tucson, Arizona, HTG’s mission is to empower precision medicine at the local level. In 2013 the company commercialized its HTG Edge instrument platform and a portfolio of RNA assays that leverage HTG’s proprietary nuclease protection chemistry. HTG’s product offerings have since expanded to include its HTG EdgeSeq product line, which automates sample and targeted library preparation for next-generation sequencing.

Additional information is available at


Posted in AZBio News.